Cadila Healthcare has received phase 1 clinical trial permission from the DCGI for Zyog1, a novel, oral, anti-diabetic molecule. Zydus Research Centre has designed and developed it by using a unique platform technology. The new class of anti-diabetic drugs called Glucagon Like Peptide-1 (GLP-1) agonists came to the fore in May 2005 when the first molecule of this class was approved by the US FDA. GLP-1 agonists are being used to treat people with type 2 diabetes who have not been able to control their blood sugar levels with oral medicines. It is an injectible which acts like the natural hormones in the body that lowers blood sugar.

Zyog1 would represent a next generation GLP-1 agents, as it would not have to be injected but can be taken orally. Zyogi1, when administered by oral route demonstrated beneficial effects in pre-clinical models on glucose reduction, HbA1c reduction and showed an added benefit of weight loss. Additionally, it has displayed a differentiated pre-clinical safety profile with no nausea-like symptoms in the pre-clinical studies.

Pankaj R Patel, chairman and managing director, said, “The discovery of the novel oral GLP-1 agonist, Zyog1, using our own unique, discovery platform technology, is a significant achievement for us. This novel molecule would address unmet medical needs in treating diabetes and hold promising potential in the anti-diabetic and anti-obesity market.”

Zyog1 is the latest addition to the group's strong research pipeline of NMEs in clinical development. The NME – ZYH1, for treating dyslipidemia is undergoing phase III clinical trials. ZYI, the anti-inflammatory and pain management compound is currently in phase II clinical trials.

The Zydus Research Centre has over discovery programmes on with several candidates in the pre-clinical development stage focused on metabolic, cardiovascular, pain, and inflammation therapeutic areas.